Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN 10 MG ONCE DAILY ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

Intervention/treatment:
FORXIGA (DAPAGLIFLOZIN)
Medical condition:
TYPE 2 DIABETES
Protocol code:
D1693C00001
Control number:
164297
Status:
Closed
Approved:
May 21, 2013
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT01730534
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 130 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Study Leader
Organization
AstraZeneca
Phone:
+49 4103 708 3792
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2H 2G4
Research Site
Calgary, Alberta, T2T 5C7

British Columbia

Research Site
New Westminster, British Columbia, V3L 3W5
Research Site
Surrey, British Columbia, V3V 0C6

Manitoba

Research Site
Winnipeg, Manitoba, R3E 3P4

New Brunswick

Research Site
Moncton, New Brunswick, E1G 1A7

Newfoundland and Labrador

Research Site
Mount Pearl, Newfoundland and Labrador, A1N 1W7
Research Site
St. John's, Newfoundland and Labrador, A1A 3R5

Nova Scotia

Research Site
Halifax, Nova Scotia, B3H 1V7
Research Site
Sydney Mines, Nova Scotia, B1V 2L2

Ontario

Research Site
Brampton, Ontario, L6S 0C6
Research Site
Brampton, Ontario, L6W 2X7
Research Site
Brampton, Ontario, L6Z 4N5
Research Site
Cambridge, Ontario, N1R 6V6
Research Site
Cambridge, Ontario, N1R 7L6
Research Site
Concord, Ontario, L4K 4M2
Research Site
London, Ontario, N5W 6A2
Research Site
London, Ontario, N6A 4V2
Research Site
London, Ontario, N6A 5A5
Research Site
London, Ontario, N6G 2M1
Research Site
North York, Ontario, M3J 1N2
Research Site
Oakville, Ontario, L6M 1M1
Research Site
Oshawa, Ontario, L1J 2K1
Research Site
Scarborough Village, Ontario, M1E 5E9
Research Site
Smiths Falls, Ontario, K7A 4W8
Research Site
Toronto, Ontario, M4G 3E8
Research Site
Toronto, Ontario, M5C 2T2
Research Site
Toronto, Ontario, M5T 3L9

Quebec

Research Site
Chicoutimi, Quebec, G7H 7K9
Research Site
Laval, Quebec, H7T 2P5
Research Site
Lévis, Quebec, G6V 4Z5
Research Site
Longueuil, Quebec, J4M 2X1
Research Site
Montreal, Quebec, H1M 1B1
Research Site
Montreal, Quebec, H1T 1C8
Research Site
Montreal, Quebec, H2W 1R7
Research Site
Montreal, Quebec, H4A 3J1
Research Site
Pointe-Claire, Quebec, H9R 3J1
Research Site
Québec, Quebec, G1G 3Y8
Research Site
Québec, Quebec, G1N 4V3
Research Site
Québec, Quebec, G1V 4G2
Research Site
Québec, Quebec, G1V 4G5
Research Site
Saint-Charles-Borromée, Quebec, J6E 6J2
Research Site
Saint-Georges, Quebec, G5Y 4T8
Research Site
Sherbrooke, Quebec, J1G 5K2
Research Site
Sherbrooke, Quebec, J1H 5N4
Research Site
Sherbrooke, Quebec, J1J 2E3
Research Site
Terrebonne, Quebec, J6V 2H2
Research Site
Laval, Quebec, H7M3L9

Saskatchewan

Research Site
Regina, Saskatchewan, S4P 0W5
Research Site
Saskatoon, Saskatchewan, S7H 5M3

Results

See the results from the trial NCT01730534. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?